Physician profile
Daniela Balint
NPI 1154503233
$2,795.15
in general payments reported to CMS, 2019-2025
10 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $63.22 · 2021: $174 · 2022: $219 · 2023: $801 · 2024: $388 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $715.09 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $639.02 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $555.55 | 2021-2025 | Caplyta |
| Abbvie INC. | $340.98 | 2023-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $203.36 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $107.94 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $64.16 | 2019-2023 | Austedo Xr |
| Alkermes, INC. | $29.39 | 2023 | Aristada, Lybalvi |
| Allergan, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Balint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.